What is the 13F Pro Quality Score for SER?

13F Pro ranks Serina Therapeutics, Inc. (SER) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SER's current score at https://13fpro.ai/research/SER (free sign-up required for the full ranking).

Where does 13F Pro source SER data?

All Serina Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Serina Therapeutics, Inc. files with the SEC under CIK 1708599. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SER in?

Serina Therapeutics, Inc. (SER) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SER research updated on 13F Pro?

SER's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Serina Therapeutics, Inc.(SER)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1708599 SER stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $3.2M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SER Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Serina Therapeutics, Inc. (SER), a Healthcare sector company. SER is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $3.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Serina Therapeutics, Inc. reports net income of $-6.9M, free cash flow of $-4.6M. Top institutional holders of SER by reported 13-F value include Sio Capital Management,, VANGUARD CAPITAL MANAGEMENT, Waverly Advisors,, based on the most recent SEC filings. SER trades on the NYSE exchange and files with the SEC under CIK 1708599. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SER daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Serina Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-6.9M

Free Cash Flow

Q1 2026

$-4.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-95.9% YoY

$130.0KFY 2025

FY20 $361.0KFY22 $34.0KFY23 $3.2MFY25 $130.0K

Net Income

-464.1% YoY

$-19.2MFY 2025

FY20 $-10.9MFY22 $-10.5MFY23 $5.3MFY25 $-19.2M

Operating Income

-667.7% YoY

$-24.0MFY 2025

FY20 $-10.1MFY22 $-7.0MFY23 $-3.1MFY25 $-24.0M

EPS (Diluted)

-361.6% YoY

$-1.91FY 2025

FY20 —FY22 $-9.70FY23 $0.73FY25 $-1.91

Total Assets

-22.5% YoY

$7.0MFY 2025

FY20 $3.9MFY22 $3.2MFY23 $9.0MFY25 $7.0M

Total Debt

—FY 2025

FY20 —FY22 $18.1MFY23 —FY25 —

Op. Cash Flow

-625.2% YoY

$-18.0MFY 2025

FY20 $-7.8MFY22 $-5.9MFY23 $-2.5MFY25 $-18.0M

Metric	FY 2025	FY 2023	FY 2022	FY 2020	FY 2018	FY 2017
Revenue	$130.0K -95.9%	$3.2M +9173.5%	$34.0K -90.6%	$361.0K -74.1%	$1.4M -0.6%	$1.4M
Net Income	$-19.2M -464.1%	$5.3M +150.4%	$-10.5M +3.7%	$-10.9M -44.8%	$-7.5M -14.0%	$-6.6M
Operating Income	$-24.0M -667.7%	$-3.1M +55.1%	$-7.0M +30.9%	$-10.1M +10.2%	$-11.2M -68.8%	$-6.7M
EPS (Diluted)	$-1.91 -361.6%	$0.73 +107.5%	$-9.70	—	—	—
Total Assets	$7.0M -22.5%	$9.0M +176.7%	$3.2M -17.4%	$3.9M -63.2%	$10.7M +10.8%	$9.6M
Total Debt	—	—	$18.1M	—	—	—
Operating Cash Flow	$-18.0M -625.2%	$-2.5M +58.3%	$-5.9M +24.0%	$-7.8M +2.2%	$-8.0M -27.2%	$-6.3M

AI Insight: SER Financial Trends

Pre-revenue biotech burning cash steadily with no material progress toward commercialization or profitability.

• Revenue remains at $0M across all reported quarters through Q1 2026; no commercial traction evident.

• Operating cash outflow stable at $3M–$8M per quarter; Q1 2026 burn rate $5M with no revenue offset.

• Net losses ranging $3M–$7M quarterly; no quarter achieved profitability since Q2 2024.

⚠ Equity swung from negative $16M (Q2 2024) to $0M–$2M; minimal buffer against prolonged cash burn.

⚠ Operating cash outflow widened to $6M in Q4 2025, signaling potential acceleration in cash consumption.

AI Insight: SER Ratio Trends

Data set too sparse to identify reliable trends — only ROA available across three non-contiguous quarters, with extreme volatility and no other profitability or efficiency metrics populated.

• ROA swung from -14.0% (Q2 2024) to +75.9% (Q3 2024), then deteriorated sharply to -77.9% TTM (Mar 2026).

⚠ TTM ROA of -77.9% indicates material asset losses or negative earnings; underlying drivers unclear without income/balance-sheet detail.

⚠ Absence of OpMargin, NPM, ROE, ROIC, and leverage data across Q4 2024–Q1 2026 prevents assessment of operational or capital efficiency trends.

Get alerted when SER's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Serina Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SER

Sio Capital Management, LLC
$1.9M1,000,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$308.7K159,136 sh
Waverly Advisors, LLC
$130.9K67,492 sh
GEODE CAPITAL MANAGEMENT, LLC
$126.0K64,973 sh
BlackRock, Inc.
$113.0K58,264 sh
JANE STREET GROUP, LLC
$76.9K39,653 sh
Keel Point, LLC
$41.7K21,508 sh
VANGUARD FIDUCIARY TRUST CO
$38.8K20,009 sh
Avidian Wealth Solutions, LLC
$36.5K18,800 sh
STATE STREET CORP
$24.8K12,758 sh

Fund	Value	Shares
Sio Capital Management, LLC	$1.9M	1,000,000
VANGUARD CAPITAL MANAGEMENT LLC	$308.7K	159,136
Waverly Advisors, LLC	$130.9K	67,492
GEODE CAPITAL MANAGEMENT, LLC	$126.0K	64,973
BlackRock, Inc.	$113.0K	58,264
JANE STREET GROUP, LLC	$76.9K	39,653
Keel Point, LLC	$41.7K	21,508
VANGUARD FIDUCIARY TRUST CO	$38.8K	20,009
Avidian Wealth Solutions, LLC	$36.5K	18,800
STATE STREET CORP	$24.8K	12,758

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SER on your watchlist

Track score changes the day Serina Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SER a good stock to buy?

13F Pro's AI-powered analysis of Serina Therapeutics, Inc. (SER) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SER are available on the SER stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SER?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SER. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Serina Therapeutics, Inc.'s investment landscape.